Insider buying last 90 days
No open-market insider purchases were filed for CAH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CAH insider filing, plotted on the chart in Gekko.Open CAH in Gekko
NYSE: CAH
Cardinal Health (CAH) Stock Analysis & Forecast
$225.38−0.96 (−0.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Gekko Brief
AI summaryCardinal Health closes at $225.38, down 0.4%, sitting between its 50-day average of $233.55 and 200-day average of $216.82. The GekkoIndex reads 69.7, placing the stock in the Accumulation zone, while Gekko Fair Value stands at $387, a gap of -41.8% from the current price. Over the past year the stock has returned 51.6%, though the one-month return is -4% against a typical 20-day move of 4.6%.
News flow this week centers on fiscal 2027 guidance and segment performance. Cardinal Health projects 13-15% adjusted EPS growth for fiscal 2027, tied to operating income growth across its business segments, and reiterates a longer-term EPS growth target of 12-14%. CEO Jason Hollar pointed to double-digit earnings growth across each of the company's five operating segments in fiscal 2026, with fiscal 2027 guidance reflecting growth from what he called a more normalized base. Separately, the company addressed how IRA pricing changes may pressure Pharma revenues while it works to protect profitability through compensation and distribution agreements, and Debbie Weitzman of Cardinal Health was named incoming chair of the Healthcare Distribution Alliance board.
Looking ahead, the next earnings date falls on 29 October 2026, before the open, which is 39 days away and outside a typical 20-trading-day holding window; the prior quarter's EPS of $2.60 beat the $2.42 estimate with a -1.3% reaction, and the company has beaten estimates in 8 of the last 8 quarters. Seasonality over this stretch has averaged a 0.7% gain across 5 years, rising in 4 of them. Analyst coverage from 14 firms shows 12 buy and 2 hold ratings, with a consensus target of $270.94.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $225.38200-day averageGekko Fair Value $387.00
Key stats
- Market cap
- $52.79B
- P/E ratio
- 32.2
- Forward P/E
- 18.5
- EPS, TTM
- $7.23
- Revenue, TTM
- $254.2B
- Profit margin
- 0.7%
- Dividend yield
- 0.88%
- Beta
- 0.52
- Volume
- 4.09M avg 1.59M
- 1-year return
- +51.6%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.6%
- 50-day average
- $233.55
- 200-day average
- $216.82
- Next earnings
- Oct 29 before open
- Shares outstanding
- 232.6M
Cardinal Health swing-trade checklist
Cardinal Health scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $225.38 sits between the 50-day ($233.55) and 200-day ($216.82) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.7, Accumulation
Reading 69.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
41.8% below
Price is 41.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cardinal Health stock chart and price history
Cardinal Health closed at $225.38 on Sep 18, 2026, +51.6% over the past year, inside a 52-week range of $145.87 to $258.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.0%
- 3 months
- +1.6%
- 6 months
- +6.9%
- 1 year
- +51.6%
The full CAH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CAH in Gekko
Follow Cardinal Health through every session
Put CAH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CAH in GekkoFree for 7 days. No credit card required.
About Cardinal Health
Cardinal Health moves medical and pharmaceutical goods to a wide range of healthcare settings, reaching customers not only in the United States but also in Canada, Europe, Asia, and beyond. Hospitals, clinics, pharmacies, surgical centers, labs, doctors' offices, and even people being treated at home all rely on it for supplies and support. Its name is tied to the large-scale handling of drugs and medical products that keep other parts of the healthcare world running.
Two divisions make up its operations. One handles pharmaceuticals, covering brand-name, generic, and specialty drugs plus everyday health items sold over the counter, and it also runs nuclear pharmacy sites, repackages certain drugs and consumer goods, and offers services such as therapy management and pharmacy oversight for hospitals and drug manufacturers. The other division makes and distributes its own line of medical and surgical supplies, from gloves and syringes to wound dressings and protective wear, while also carrying other companies' brands and building supply arrangements for hospitals, surgery centers, and labs.
The company traces back to 1979 and runs its operations from Dublin, Ohio. Its stock trades on the NYSE under the ticker CAH.
- Listed
- NYSE
- Sector
- Distribution services
- Industry
- Medical distributors
- Website
- cardinalhealth.com
Cardinal Health GekkoIndex: the smart money zone
Cardinal Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.7, in the Accumulation zone, up 10.9 points over five sessions.
69.7Accumulation
Up 10.9 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 18 | +1.8% | +3.5% | ||
| Accumulation (current zone) | 166 | 0.0% | +2.1% | ||
| Neutral | 389 | +1.1% | +3.9% | ||
| Distribution | 81 | −0.3% | −0.8% | ||
| Selling | 8 | Too few readings yet | |||
Average CAH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CAH price, zone by zone.Track CAH in Gekko
Is Cardinal Health stock overvalued? Gekko Fair Value
Cardinal Health trades 41.8% below Gekko Fair Value of $387.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cardinal Health shares are worth, recalculated every trading day.
$387.00
Gekko Fair Value, Sep 18, 2026
41.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CAH in Gekko
Cardinal Health insider and Congress trading
No open-market insider purchases were filed for Cardinal Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CAH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CAH, plotted on the chart in Gekko.Open CAH in Gekko
Buybacks
Cardinal Health has been buying back its own shares.
- Latest authorization
- $5.00B, Aug 11, 2026
- Bought back, quarter ended Jun 30, 2026
- $350.0M
- As a share of market cap
- 0.66%
- Trailing four quarters
- $1.36B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds CAH.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Cardinal Health earnings: next date and track record
Cardinal Health reports on Oct 29, 2026, before the open (39 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 39 days away
- EPS estimate
- $2.92
- Revenue estimate
- $66.71B
8 of 8reports beat the EPS estimate
±6.1%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Cardinal Health reported a strong fiscal 2026 fourth quarter and year, driven by broad-based demand across Pharmaceutical and Specialty Solutions and progress in Global Medical Products and Distribution (GMPD). Management highlighted strong volume, gross profit growth, operating income up 30% year/year, EPS growth (40% quarter, 37% year), and $5 billion adjusted free cash flow for the year. Specialty businesses delivered high growth (above 20%) and Other growth businesses produced double-digit profit growth. Management emphasized continued investments in automation, technology, capacity and targeted M&A, while returning capital to shareholders. Fiscal '27 outlook is constructive: management expects momentum to continue but not at the outsized levels seen in some of fiscal '26, with modest bolt-on M&A carryover benefits. Management reiterated disciplined investment priorities and confidence in execution while acknowledging regulatory and input-cost headwinds (IRA/340B, tariffs, commodity and fuel costs, WACC/pricing impacts).
- Guidance
- Highlights disclosed or referenced for fiscal 2027: - Specialty/Pharma AOI growth guide referenced by analysts as ~8%–11% (management confirmed momentum but not assuming outsized demand). - "Other" segment: revenue growth 11%–13% and profit growth 15%–18%. - Management expects 2–3 percentage points of positive benefit from M&A completed in fiscal '26; no material new M&A assumed for fiscal '27. - Confirmed durable tax rate around ~19% for fiscal '27 (vs. prior higher rate). - Company reaffirmed long-term non-GAAP EPS growth target of ~12%–14% per year (no other updated long-term guidance provided). - IRA/WACC and tariff recovery impacts are modeled into fiscal '27 guidance; commodity/input cost pressures could push results toward the lower end of ranges if sustained.
- Risks flagged
- Key risks discussed: - Regulatory uncertainty: IRA impacts, potential 340B reform, other federal actions affecting pricing and reimbursement. - Tariffs and tariff recovery timing (tariff refund benefit noted as nonrecurring tailwind). - WACC/pricing changes tied to IRA and manufacturer dynamics affecting revenue. - Input cost pressures (diesel, oil-based polymers, resins) and logistics costs that could compress margins or push results toward the low end of guidance. - Potential variability in demand (management assumes strong but not outsized demand).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | $2.60 est $2.42 | — est $65.15B | −1.3% |
| Apr 30, 2026 | $3.17 est $2.79 | $60.94B est $62.10B | −3.7% |
| Feb 5, 2026 | $2.63 est $2.37 | $65.63B est $65.08B | +9.4% |
| Oct 30, 2025 | $2.55 est $2.17 | $64.01B est $59.24B | +16.0% |
| Aug 12, 2025 | $2.08 est $2.03 | $60.16B est $60.89B | −6.1% |
| May 1, 2025 | $2.10 est $1.69 | $54.88B est $55.39B | +5.8% |
| Jan 30, 2025 | $1.93 est $1.76 | $55.26B est $55.02B | −3.2% |
| Nov 1, 2024 | $1.88 est $1.62 | $52.28B est $50.90B | +3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cardinal Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Cardinal Health is $270.94, +20.2% from the last close, from 14 firms rating the stock in the last 90 days.
$270.94consensus 12-month target, +20.2% from the last close
Now $225.38Avg $270.94
Low $250High $292
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | Wells Fargo | $277 | +22.9% |
| Aug 19 | RBC Capital | $276 | +22.5% |
| Aug 18 | Barclays | $275 | +22.0% |
| Aug 17 | J.P. Morgan | $260 | +15.4% |
| Aug 13 | Deutsche Bank | $261 | +15.8% |
+2.1%average 20-day move after past Accumulation readings
+0.7%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cardinal Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Cardinal Health averaged +0.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.5% | 2 of 5 |
| Next 10 trading days | −0.7% | 1 of 5 |
| Next 15 trading days | +1.4% | 4 of 5 |
| Next 20 trading days | +0.7% | 4 of 5 |
| Next 30 trading days | +6.6% | 3 of 5 |
For scale, CAH’s typical 20-trading-day move in either direction is about 4.6%.
Cardinal Health market cap and key statistics
Cardinal Health’s market cap is $52.79B, with a P/E ratio of 32.2 and revenue of $254.2B over the last twelve months.
Valuation
- Market cap
- $52.79B
- P/E ratio
- 32.2
- Forward P/E
- 18.5
- EPS, TTM
- $7.23
- Gekko Fair Value
- $387.00
Trading
- Volume
- 4.09M
- Avg volume, 20 days
- 1.59M
- 52-week high
- $258.30
- 52-week low
- $145.87
- Shares outstanding
- 232.6M
Financials
- Revenue, TTM
- $254.2B
- Profit margin
- 0.7%
- Return on equity
- 0%
- Quarterly earnings growth, YoY
- +68.8%
Risk and income
- Beta
- 0.52
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.6%
- Dividend yield
- 0.88%
Cardinal Health stock news this week
Coverage of Cardinal Health this week reads positive: 3 positive, 0 neutral and 1 negative headlines.
- Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum BuildsYahoo Finance, Sep 19
- Cardinal Health Sees Growth Normalize as Specialty, At-Home Investments ExpandMarketBeat, Sep 19
- Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?Zacks Investment Research, Sep 16
- Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research, Sep 15
- Cardinal Health, Inc. (CAH) Presents at 2026 Global Healthcare Conference TranscriptSeeking Alpha, Sep 15
- Cardinal Health’s Debbie Weitzman and Value Drug Company’s Rick Seipp to lead HDA boardChain Drug Review, Sep 15
Cardinal Health peers
Cardinal Health’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MCKMcKesson | Accumulation | 14.1% below |
| CORCencora | Accumulation | 28.7% below |
| HSICHenry Schein | Buying | 0.1% above |
A peer links to its own page where one exists.
Cardinal Health stock FAQ
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is $52.79B at the Sep 18, 2026 close of $225.38, with 232.6M shares outstanding. The shares trade on a P/E ratio of 32.2.
What is the Cardinal Health stock forecast?
The consensus analyst 12-month price target for Cardinal Health is $270.94, +20.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 12 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cardinal Health stock overvalued or undervalued?
On Gekko’s estimate Cardinal Health is undervalued: the Sep 18, 2026 close of $225.38 is 41.8% below Gekko Fair Value of $387.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Cardinal Health report earnings next?
Cardinal Health is expected to report on Oct 29, 2026, before the market opens (39 days away). Analysts expect earnings of $2.92 per share on revenue of $66.71B. Cardinal Health beat the earnings estimate in 8 of its last 8 reports, moving 6.1% on average across the report.
What is Cardinal Health’s 52-week high and low?
Cardinal Health’s 52-week high is $258.30 and its 52-week low is $145.87; it closed at $225.38 on Sep 18, 2026, +51.6% over the past year.
Is Cardinal Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cardinal Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.